Addition of metabolite technology uniquely positions company as it expands
                  its line of predictive diagnostic tests

    EMERYVILLE, Calif., Sept. 17 /PRNewswire/ -- Tethys Bioscience, Inc.
announced today that it has acquired Lipomics Technologies of West
Sacramento, Calif. The acquisition will be finalized today upon completion
of customary closing conditions. Financial terms were not disclosed.

    The acquisition brings together Lipomics' metabolite profiling
technology with Tethys' proven expertise in the use of protein biomarkers
to create novel tests capable of accurately predicting a person's
likelihood of developing chronic diseases. Tethys launched its first such
test - the PreDx(TM) Diabetes Risk Test - earlier this year, and is working
to develop similar tests that will predict a person's likelihood of
experiencing an osteoporotic bone fracture or a major cardiac event.

    Integration of the Lipomics understanding of lipid biology with the
Tethys protein biomarker analysis capability provides the Company with
state-of-the- art technology as it extends its focus beyond diabetes. With
this combination, Tethys is uniquely positioned to develop unprecedented
insights into the biological mechanisms of a host of diseases.

    "We are very excited to add this highly complementary expertise to our
increasingly diversified technology portfolio," said Mickey Urdea, Tethys'
founder, chairman and CEO. "We believe that the best solutions for
predicting and thereby preventing a range of chronic conditions will come
from the thoughtful integration of multiple types of biomarkers - including
proteins and metabolites. The addition of Lipomics furthers our goal of
arming patients and physicians with insights that will help reduce the
incidence of preventable chronic diseases."

    With completion of the acquisition today, full integration of the
companies is well underway. Effective today, all 30 employees of Lipomics
will become part of Tethys. Steven M. Watkins, PhD., co-founder, president
and chief scientific officer of Lipomics, will assume the role of chief
technology officer at Tethys. The Lipomics facility will continue its
comprehensive and quantitative profiling of lipid metabolites as Tethys
West Sacramento.

    "From the moment we began discussions with Tethys, we were each struck
by the complementary nature of our technologies, our core skills, and our
sharp focus on addressing unmet clinical needs," Watkins said. "The
Lipomics team is delighted to become part of Tethys, and to bring our
expertise to bear on advancing the field of predictive personalized
medicine."

    About Tethys Bioscience

    Tethys Bioscience is a predictive personalized medicine company
developing novel tests which address the growing global healthcare
challenge of chronic diseases such as diabetes. Founded in 2005, the
company integrates an experienced management team, innovative research
based on sound science, a CLIA-licensed clinical laboratory, and a
commercialization team with extensive experience in diagnostic innovation.
Our partnerships with world class researchers and our solid financial
foundation will enable Tethys to help transform the management of chronic
diseases by providing personalized, preventive solutions that aid every
constituency: patients, doctors and the healthcare system as a whole.

    About Lipomics

    Lipomics Technologies provides industry-leading metabolic assessments
for drug research, clinical diagnostics and personalized medicine. The
Company's proprietary analytical technologies generate comprehensive,
accurate and quantitative profiles of lipid metabolites. Lipomics delivers
deep and rich knowledge about biological and metabolic changes induced by
disease, drug action, nutritional or lifestyle influences. In partnership
with pharmaceutical, biotechnology, and nutrition companies, Lipomics uses
its technologies to discover new diagnostic biomarkers, improve drug
discovery, develop companion diagnostics and enable individualized health
management.

    About the PreDx(TM) Diabetes Risk Test

    Tethys announced the expanded availability of its first predictive,
personalized test - the PreDx Diabetes Risk Test -- in June. The PreDx
Diabetes Risk Test is a first-of-its-kind predictive tool that delivers an
accurate assessment of an individual's risk of developing Type 2 diabetes
within the next five years. The test is performed exclusively by the Tethys
Bioscience Clinical Laboratory on routinely collected blood samples.

    The new blood test is designed to help physicians identify patients at
highest risk of developing Type 2 diabetes so that they can promote
lifestyle changes or initiate treatment plans to prevent or slow
progression to Type 2 diabetes. Numerous studies have demonstrated that
such interventions can reduce the incidence of new onset diabetes by
30-60%.



    Contacts:
    Jay Kerzner
    Director of Communications
    Tethys Bioscience
    510-420-6746
    jkerzner@tethysbio.com

    Hal Mackins
    Media Relations for Tethys
    415-994-0040
    hal.mackins@fkhealth.com

Link to this page: